Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sinapultide - Windtree Therapeutics

Next Previous
Drug Profile

Sinapultide - Windtree Therapeutics

Alternative Names: Aerosolized KL4 surfactant; AEROSURF; ATI-01; ATI-02; DSC-104; DSC-105; KL-4 lung surfactant; KL4 pulmonary surfactant; KL4 surfactant; Lucinactant; Surfaxin; Surfaxin LS

Latest Information Update: 23 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Scripps Research Institute
  • Developer Discovery Laboratories; University of Pennsylvania; Windtree Therapeutics
  • Class Amino acids; Anti-inflammatories; Antiasthmatics; Peptides; Surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchopulmonary dysplasia; Neonatal respiratory distress syndrome; Acute lung injury; Meconium aspiration syndrome; Adult respiratory distress syndrome; Cystic fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Neonatal respiratory distress syndrome; SARS-CoV-2 acute respiratory disease
  • No development reported Acute lung injury; Adult respiratory distress syndrome; Bronchopulmonary dysplasia; Chronic obstructive pulmonary disease; Cystic fibrosis; Lung disorders; Reperfusion injury
  • Discontinued Asthma; Meconium aspiration syndrome; Otitis media; Respiratory insufficiency; Rhinitis; Sinusitis

Most Recent Events

  • 16 Nov 2023 Windtree Therapeutics has patent protection for SERCA2a activator class of drug candidates in the EU and USA
  • 27 Apr 2022 Windtree Therapeutics has patent protection in USA and Europe
  • 22 Mar 2022 Adverse events data from a phase II trial in SARS-COV-2 acute respiratory disease released by Windtree Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top